Novo Nordisk announced that new information from its world-leading portfolio in metabolic and cardiovascular health will be presented at the forthcoming American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US, 20 – 23 June 2025.
29 abstracts will be being given, including trials of weight loss effectiveness of higher dose Wegovy® (semaglutide 7.2 mg) in adults with obesity (STEP UP) and adults with obesity and type 2 diabetes (STEP UP T2D) as an additional choice for those who need more weight loss. New evidence will provide further proof of semaglutide’s wider cardiovascular and renal benefits in type 2 diabetes patients through subgroup analyses of the SOUL, STRIDE and FLOW trials and data from additional real-world experience with semaglutide 2.4 mg.
Aiming to address individual needs and preferences for better health, we look forward to providing a higher dose of Wegovy® (semaglutide 7.2 mg) for people with obesity in need of more significant weight loss, alongside the broader health benefits seen with semaglutide.
Semaglutide has shown comprehensive and disease-modifying effects across the metabolic and cardiovascular health spectrum, and the data presented at ADA 2025 for Wegovy®, Rybelsus®, and Ozempic® will add to this evidence base as we aspire to a future where semaglutide is a foundational therapy that can provide people with comprehensive protection, early enough to make a difference.
Ludovic Helfgott
The data from the CagriSema REDEFINE 1 and 2 trials are the first-ever Phase 3 data to be presented on a combination of a GLP-1 and amylin receptor agonist, providing insight into the potential for transformation with this investigational product. Pipeline candidate amycretin data will also be shown, highlighting Novo Nordisk’s obesity innovation and personalized healthcare solution focus.
We recognise the complex interplay between cardiovascular and metabolic diseases, including type 2 diabetes and obesity, which require a personalised treatment approach,
As we look to further build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease.
Martin Holst Lange
Last Modified:
